Tursynbek Nurmagambetov1, Olga Khavjou2, Louise Murphy3, Diane Orenstein4. 1. a Division of Environmental Hazards and Health Effects, Centers for Disease Control and Prevention , Atlanta , GA , USA. 2. b RTI International, Research Triangle Park , NC , USA. 3. c Division of Population Health, Centers for Disease Control and Prevention , Atlanta , GA , USA. 4. d Division of Community Health, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Abstract
OBJECTIVE: For medically treated asthma, we estimated prevalence, medical and absenteeism costs, and projected medical costs from 2015 to 2020 for the entire population and separately for children in the 50 US states and District of Columbia (DC) using the most recently available data. METHODS: We used multiple data sources, including the Medical Expenditure Panel Survey, U.S. Census Bureau, Kaiser Family Foundation, Medical Statistical Information System, and Current Population Survey. We used a two-part regression model to estimate annual medical costs of asthma and a negative binomial model to estimate annual school and work days missed due to asthma. RESULTS: Per capita medical costs of asthma ranged from $1,860 (Mississippi) to $2,514 (Michigan). Total medical costs of asthma ranged from $60.7 million (Wyoming) to $3.4 billion (California). Medicaid costs ranged from $4.1 million (Wyoming) to $566.8 million (California), Medicare from $5.9 million (DC) to $446.6 million (California), and costs paid by private insurers ranged from $27.2 million (DC) to $1.4 billion (California). Total annual school and work days lost due to asthma ranged from 22.4 thousand (Wyoming) to 1.5 million days (California) and absenteeism costs ranged from $4.4 million (Wyoming) to $345 million (California). Projected increase in medical costs from 2015 to 2020 ranged from 9% (DC) to 34% (Arizona). CONCLUSION: Medical and absenteeism costs of asthma represent a significant economic burden for states and these costs are expected to rise. Our study results emphasize the urgency for strategies to strengthen state level efforts to prevent and control asthma attacks.
OBJECTIVE: For medically treated asthma, we estimated prevalence, medical and absenteeism costs, and projected medical costs from 2015 to 2020 for the entire population and separately for children in the 50 US states and District of Columbia (DC) using the most recently available data. METHODS: We used multiple data sources, including the Medical Expenditure Panel Survey, U.S. Census Bureau, Kaiser Family Foundation, Medical Statistical Information System, and Current Population Survey. We used a two-part regression model to estimate annual medical costs of asthma and a negative binomial model to estimate annual school and work days missed due to asthma. RESULTS: Per capita medical costs of asthma ranged from $1,860 (Mississippi) to $2,514 (Michigan). Total medical costs of asthma ranged from $60.7 million (Wyoming) to $3.4 billion (California). Medicaid costs ranged from $4.1 million (Wyoming) to $566.8 million (California), Medicare from $5.9 million (DC) to $446.6 million (California), and costs paid by private insurers ranged from $27.2 million (DC) to $1.4 billion (California). Total annual school and work days lost due to asthma ranged from 22.4 thousand (Wyoming) to 1.5 million days (California) and absenteeism costs ranged from $4.4 million (Wyoming) to $345 million (California). Projected increase in medical costs from 2015 to 2020 ranged from 9% (DC) to 34% (Arizona). CONCLUSION: Medical and absenteeism costs of asthma represent a significant economic burden for states and these costs are expected to rise. Our study results emphasize the urgency for strategies to strengthen state level efforts to prevent and control asthma attacks.
Entities:
Keywords:
Prevalence; medical expenditure; missed school days; payer
Authors: Erika Garcia; Robert Urman; Kiros Berhane; Rob McConnell; Frank Gilliland Journal: Proc Natl Acad Sci U S A Date: 2019-07-22 Impact factor: 11.205
Authors: Quan Dong; Baichen Li; R Scott Downen; Nam Tran; Elizabeth Chorvinsky; Dinesh K Pillai; Mona E Zaghloul; Zhenyu Li Journal: IEEE Sens J Date: 2020-07-17 Impact factor: 3.301
Authors: Olga A Khavjou; Wayne L Anderson; Amanda A Honeycutt; Laurel G Bates; NaTasha D Hollis; Scott D Grosse; Hilda Razzaghi Journal: Public Health Rep Date: 2021-03-05 Impact factor: 3.117
Authors: Harsheen Kaur; Sunghwan Sohn; Chung-Il Wi; Euijung Ryu; Miguel A Park; Kay Bachman; Hirohito Kita; Ivana Croghan; Jose A Castro-Rodriguez; Gretchen A Voge; Hongfang Liu; Young J Juhn Journal: BMC Pulm Med Date: 2018-02-13 Impact factor: 3.317
Authors: Hatice S Zahran; Cathy M Bailey; Scott A Damon; Paul L Garbe; Patrick N Breysse Journal: MMWR Morb Mortal Wkly Rep Date: 2018-02-09 Impact factor: 17.586
Authors: Brian C Hsia; Anjani K Singh; Obumneme Njeze; Emine Cosar; Wenzhu B Mowrey; Jonathan Feldman; Marina Reznik; Sunit P Jariwala Journal: Ann Allergy Asthma Immunol Date: 2020-07-22 Impact factor: 6.347